Loading resource…

School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, State University of New York; Detroit Medical Center; Department of Internal Medicine, Medical School, Universidade Federal do Rio Grande do Sul; Infectious Diseases Institute, Rambam
The guidelines provide recommendations for the use of polymyxins in treating infections caused by multidrug-resistant organisms. They address the complexities of treatment regimens, particularly in cases of carbapenem-resistant infections. The document emphasizes the importance of considering the site of infection and the susceptibility of pathogens when deciding on therapy. It aims to guide clinicians in making informed decisions regarding polymyxin-based therapies.
No account needed
Answers use this document only.
Resources from the same specialty and type. Curated links will replace these when added.
Documents that extend or complement this resource.

2026 WHO Malaria Guideline
Same clinical topic · Infectious Diseases

Updated Malaria Treatment Guidelines
Same clinical topic · Infectious Diseases

Guidelines for the management of asymptomatic sexually transmitted infections
Same clinical topic · Infectious Diseases

National Antiretroviral Treatment Guidelines
Same clinical topic · Infectious Diseases

Uganda Malaria Control Program Guidelines 2022
Same clinical topic · Infectious Diseases

Uganda National TB and Leprosy Control Programme Manual
Same clinical topic · Infectious Diseases

Management of severe malaria: a practical handbook
Same clinical topic · Infectious Diseases

Uganda Hepatitis B and C Guidelines
Same clinical topic · Infectious Diseases

Ebola Virus Disease Case Definitions
Same clinical topic · Infectious Diseases